Abstract
BACKGROUND AND OBJECTIVE:
To report five cases of iritis after intravitreal injection of bevacizumab.
PATIENTS AND METHODS:
The clinical charts of patients who received intravitreal injections of bevacizumab or ranibizumab from January 2009 to September 2011 by one physician were retrospectively reviewed.
RESULTS:
A total of 1,097 injections of bevacizumab and 571 of ranibizumab were administered. Five patients developed acute anterior uveitis and presented with severe pain, photophobia, conjunctival injection, and anterior chamber reaction 2 to 24 hours after intravitreal injection of bevacizumab. All five patients were treated with topical corticosteroids with rapid resolution of the inflammation.
CONCLUSION:
Although uncommon, acute iritis is a complication of intravitreal injection of bevacizumab.
- 1.Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113:363–372.
10.1016/j.ophtha.2005.11.019 Crossref Medline, Google Scholar - 2.Spaide RF, Laud K, Fine HF, Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006; 26:383–390.
10.1097/00006982-200604000-00001 Crossref Medline, Google Scholar - 3.Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007; 27:419–425.
10.1097/IAE.0b013e318030e77e Crossref Medline, Google Scholar - 4.Iturralde D, Spaide RF, Meyerle CB, Intravitreal bevacizumab (Avastin) treatment of macular edema in central vein occlusion: A short-term study. Retina. 2006; 26:279–284.
10.1097/00006982-200603000-00005 Crossref Medline, Google Scholar - 5.Avery RL, Pearlman J, Pieramici DJ, Intravitreal bevacizumab (Avastin) in treatment of proliferative diabetic retinopathy. Ophthalmology. 2006; 113:1695.
10.1016/j.ophtha.2006.05.064 Crossref Medline, Google Scholar - 6.CATT Research GroupMartin DF, Maguire MG, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011; 364:1897–1908.
10.1056/NEJMoa1102673 Crossref Medline, Google Scholar - 7.Wickremasinghe SS, Michalova K, Gilhotra J, Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2008; 115:1911–1915.
10.1016/j.ophtha.2008.05.007 Crossref Medline, Google Scholar - 8.Pieramici DJ, Avery RL, Castellarin AA, Nasir MA, Rabena M. Case of anterior uveitis after intravitreal injection of bevacizumab. Retina. 2006; 26:841–842.
10.1097/01.iae.0000234629.22614.cd Crossref Medline, Google Scholar - 9.Jonas JB, Spandau UH, Rensch F, Von Baltz S, Schlichtenbrede F. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther. 2007; 23:240–242.
10.1089/jop.2006.0146 Crossref Medline, Google Scholar - 10.Shima C, Sakaguchi H, Gomi F, Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008; 86:372–376.
10.1111/j.1600-0420.2007.01067.x Crossref Medline, Google Scholar - 11.Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246:779–781.
10.1007/s00417-007-0754-7 Crossref Medline, Google Scholar - 12.Sato T, Emi K, Ikeda T, Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology. 2010; 117:512–516.
10.1016/j.ophtha.2009.07.041 Crossref Medline, Google Scholar - 13.Mamalis N, Edelhauser HF, Dawson DG, Chew J, LeBoyer RM, Werner L. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006; 32:324–333.
10.1016/j.jcrs.2006.01.065 Crossref Medline, Google Scholar - 14.Jabs DA, Nussenblatt RB, Rosenbaum JTStandardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol. 2005; 140:509–516.
10.1016/j.ajo.2005.03.057 Crossref Medline, Google Scholar - 15.Ho J, Loewenstein JI. Endophthalmitis associated with intravitreal injections. Int Ophthalmol Clin. 2007; 47:199–208.
10.1097/IIO.0b013e318037795f Crossref Medline, Google Scholar - 16.Fintak DR, Shah GK, Blinder KJ, Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28:1395–1399.
10.1097/IAE.0b013e3181884fd2 Crossref Medline, Google Scholar - 17.Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol. 2010; 45:239–242.
10.3129/i10-013 Crossref Medline, Google Scholar - 18.Bakri SJ, Snyder MR, Reid JM, Pullido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114:855–859.
10.1016/j.ophtha.2007.01.017 Crossref Medline, Google Scholar
